Data presented at Keystone Symposium on
Neurodegenerative Diseases
TORONTO and CAMBRIDGE, MA, June 27,
2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB:
ARFXF), a biotechnology company focused on the discovery and
development of antibody therapeutics targeting toxic oligomers
implicated in the development of neurodegenerative diseases,
presented data for its lead program, PMN310 for Alzheimer's
disease, at last week's Keystone Symposium on Neurodegenerative
Diseases. ProMIS' Chief Development Officer Dr. Johanne Kaplan presented data showing that
PMN310 possesses superior selectivity for amyloid beta toxic
oligomers (AßOs) and improved therapeutic potential compared with
other Aß-directed antibodies. Dr. Kaplan shares her perspective on
the most notable research stemming from the conference on Episode 8
of the podcast Saving Minds, available on Apple Podcasts and
Spotify.
"Researchers from every continent in the world, except
Antarctica, lingered far into the
evening to view posters, share perspectives and discuss future
therapy directions," indicated Dr. Johanne
Kaplan, Keystone presenter
and Chief Development Officer at ProMIS Neurosciences. "There was
genuine optimism and a sense of momentum around therapy development
efforts for neurodegenerative diseases. There was a general
consensus for the need to selectively target the propagating forms
of toxic proteins in pursuit of disease modifying therapies: Our
data on PMN310 were very well received."
Dr. Kaplan's poster, "Selective targeting of HHQK conformational
epitope in amyloid-beta oligomer species by PMN310, a monoclonal
antibody rationally designed for greater therapeutic potency in
Alzheimer's disease," presented data indicating that PMN310
possesses:
- Superior selectivity for toxic AßOs in Alzheimer's brain
samples
- Ability to neutralize the neurotoxicity and propagation of
AßOs
- Potential to safely administer high doses of PMN310 (reduced
risk of brain edema) and achieve greater therapeutic potency
compared with other Aß-directed antibodies.
The conference, Keystone Symposia on Molecular and Cellular
Biology, Neurodegenerative Diseases: New Insights and Therapeutic
Opportunities, took place June 16-20,
2019 at Keystone Resort in Keystone, Colorado. To access Dr. Kaplan's
podcast, Saving Minds, visit iTunes or Spotify.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc.
is a development stage biotechnology company focused on discovering
and developing antibody therapeutics selectively targeting toxic
oligomers implicated in the development and progression of
neurodegenerative diseases, in particular Alzheimer's disease (AD),
amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD).
The Company's proprietary target discovery platform is based on the
use of two complementary thermodynamic, computational discovery
engines - ProMIS and Collective Coordinates - to predict novel
targets known as Disease Specific Epitopes on the molecular surface
of misfolded proteins. Using this unique precision approach, the
Company is developing novel antibody therapeutics for AD, ALS and
PD. ProMIS is headquartered in Toronto,
Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on
the Toronto Stock Exchange under the symbol PMN, and on the OTCQB
Venture Market under the symbol ARFXF.
To learn more, visit us at www.promisneurosciences.com, follow
us on Twitter and LinkedIn.
The TSX has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. This information
release contains certain forward-looking information. Such
information involves known and unknown risks, uncertainties and
other factors that may cause actual results, performance or
achievements to be materially different from those implied by
statements herein, and therefore these statements should not be
read as guarantees of future performance or results. All
forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently
available to it as well as other factors. Readers are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. Due to risks and
uncertainties, including the risks and uncertainties identified by
the Company in its public securities filings, actual events may
differ materially from current expectations. The Company disclaims
any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/promis-neurosciences-pmn310-shows-greater-therapeutic-potential-vs-other-amyloid-beta-directed-antibodies-300875589.html
SOURCE ProMIS Neurosciences Inc.